Last mentioned: Mar 26, 2026
FDA Investigation Phase
Anticipated start of formal manufacturing facility inspections and 483 issuance.
Compliance Review
Industry analysts begin evaluating the impact on ImmunityBio's internal promotional controls.
Supply Chain Sequestration
Hospitals and distributors begin identifying and removing affected lot numbers.
FDA Warning Issued
Federal health officials issue a formal warning over misleading statements made by Patrick Soon-Shiong.
Media Reports
Major outlets including Seattle Times and MedPage Today report on the regulatory crackdown.
Recall Announcement
Initial public health alerts issued regarding contaminated alcohol pads.
Injunction Issued
Federal judge grants a temporary block on the implementation of the vaccine agenda.
Marketplace Purge
Amazon begins removing thousands of listings in the Tejocote and weight-loss categories for compliance review.
Mass Public Warning
Widespread media alerts issued to consumers across the United States regarding the 'poison' supplements.
Amazon Notification
Regulators formally notify Amazon of the presence of poisonous substances in specific marketplace listings.
Initial Detection
FDA laboratory testing identifies toxic yellow oleander in weight-loss supplements.
Preliminary Hearing
Arguments heard regarding the executive branch's authority to bypass CDC/FDA protocols.
Settlement & Collaboration
Hims & Hers and Novo Nordisk announce the end of litigation and the start of a commercial partnership.
Current Status
Regulatory bodies and industry leaders report a significant decline in animal-based IND applications.
Settlement Reached
Hims & Hers agrees to stop selling compounded GLP-1s to resolve legal disputes.
Legal Challenges Filed
A coalition of health organizations and states file suit to block the agenda.
Policy Shift Announced
RFK Jr. outlines a new agenda for national vaccine oversight and safety reviews.
Supply Stabilization
FDA indicates that semaglutide shortages are easing, increasing legal pressure on compounders.
Litigation Surge
Novo Nordisk and Eli Lilly file multiple lawsuits against compounding pharmacies and telehealth firms.
FDA Shortage Updates
FDA begins removing specific GLP-1 dosages from the national shortage list.
The FDA has issued a formal warning to billionaire Patrick Soon-Shiong regarding misleading promotional statements about ImmunityBio’s bladder cancer treatment. The regulatory action highlights a growing crackdown on off-label marketing conducted through non-traditional media channels like podcasts.
A nationwide recall of alcohol prep pads has been initiated following reports of life-threatening bacterial contamination. The event has triggered immediate intervention from health authorities and highlights critical vulnerabilities in medical supply chain sterility protocols.
A federal judge has issued a temporary injunction against Robert F. Kennedy Jr.’s proposed vaccine policy changes, citing potential risks to public health infrastructure. The ruling halts the immediate implementation of the agenda while the court examines the legality of bypassing established scientific review processes.
Federal regulators have issued an urgent public health warning regarding poisonous substances found in dietary supplements sold on Amazon's marketplace. The discovery of toxic ingredients like yellow oleander in products marketed as weight-loss aids has reignited the legal debate over marketplace liability and the adequacy of automated compliance systems.
Hims & Hers Health has agreed to cease the sale of compounded GLP-1 medications as part of a legal settlement, marking a significant shift in the telehealth landscape. This move follows intense regulatory scrutiny and litigation regarding the legality of compounding patented weight-loss drugs during supply shortages.
Hims & Hers Health and Novo Nordisk have reached a settlement to end their legal dispute over compounded weight loss medications. The agreement transitions the relationship from adversarial litigation to a strategic collaboration, potentially reshaping the telehealth distribution model for GLP-1 drugs.
The pharmaceutical industry is undergoing a historic shift as the FDA Modernization Act 2.0 ends the decades-long mandate for animal testing. This transition toward New Approach Methodologies (NAMs) like organ-on-a-chip and AI modeling is redefining the legal and regulatory requirements for drug safety validation.
This page surfaces every story mentioning FDA across our legal coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running legal beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where FDA was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |